Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.

Pitcher A. et al, (2022), Lancet

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368

Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.

Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.

Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.

Scally B. et al, (2018), Lancet Gastroenterol Hepatol, 3, 231 - 241

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Coxib and traditional NSAID Trialists' (CNT) Collaboration None. et al, (2013), Lancet, 382, 769 - 779

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Antithrombotic Trialists' (ATT) Collaboration None. et al, (2009), Lancet, 373, 1849 - 1860

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

Kearney PM. et al, (2006), BMJ, 332, 1302 - 1308

An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales.

Roderick P. et al, (2005), Health Technol Assess, 9, 1 - 178

Towards evidence-based guidelines for the prevention of venous thromboembolism: Systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis

Roderick P. et al, (2005), Health Technology Assessment, 9

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Baigent C. et al, (1998), BMJ, 316, 1337 - 1343

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.

(1994), Lancet, 343, 311 - 322

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.

(1992), Lancet, 339, 753 - 770

British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction.

Collins R. and Julian D., (1991), Br Heart J, 66, 250 - 255

Load More

Include forthcoming?